American Bio Medica Supplying Mexican Army with Drug Testing Products.

KINDERHOOK, N.Y. -- American Bio Medica Corporation (NASDAQ: ABMC) today announced that they have received a contract from the Mexican Army to supply them with the Company's Rapid TEC(R) product through ABMC's authorized distributor, Devor Diagnostics SA de CV. To obtain this contract, the Company's Rapid TEC product was evaluated against a number of competitive products and chosen due to its accuracy, user friendliness and cost effectiveness. The Rapid TEC product contains one individual drug-testing strip that includes the chemistry to detect more than one class of drug. The Company has already begun shipping product under this contract, the first order of which was for 52,000 units. The Mexican Army will be using ABMC's products to test new recruits and those individuals receiving promotions.

Stan Cipkowski, ABMC Chief Executive Officer stated, "This contract with the Mexican Army could not have been obtained without the efforts of our distributor, Devor Diagnostics and we thank them. We made the decision to expand our sales focus in Latin America and this expanded focus, along with the expertise and dedication of distributors such as Devor should allow us to continue to acquire more contracts like this one, and see increased sales in these territories."

For more information on ABMC or its drug testing products, please visit www.abmc.com.

About American Bio Medica Corporation

American Bio Medica Corporation is a biotechnology company that develops manufactures and markets accurate, cost-effective immunoassay diagnostic test kits, including some of the world's most effective point of collection tests for drugs of abuse. The Company and its worldwide distribution network target the workplace, government, corrections, clinical and educational markets. ABMC's Rapid Drug Screen(R), Rapid One(R), Rapid TEC and RDS(R) InCup(TM) products test for the presence or absence of drugs of abuse in urine, while OralStat(R) tests for the presence or absence of drugs of abuse in oral fluids. ABMC's Rapid Reader(TM) is a compact, portable device that, when connected to any computer, interprets the results of an ABMC drug screen, and sends the results to a data management system, enabling the test administrator to easily manage their drug testing program.

This release may contain forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ, and such differences could be material. Such risks and uncertainties include, but are not limited to, the following: continued acceptance of the Company's products, increased levels of competition in our industry, the acceptance of new products, inherent risks associated with product development and intellectual property rights, the Company's dependence on key personnel, third party sales and suppliers. There can be no assurance that the Company will be successful in addressing such risks and uncertainties and the Company assumes no duty to update any forward-looking statements based upon actual results. Investors are strongly encouraged to review the section entitled "Risk Factors" in the Company's annual report on Form 10-KSB for the fiscal year ended December 31, 2004, and quarterly reports on Form 10-QSB on file with the Securities and Exchange Commission for a discussion of risks and uncertainties that could affect operating results and the market price of the Company's common shares.